Drug resistance: Still a daunting challenge to the successful treatment of AML

B.C. Shaffer, J.-P. Gillet, C. Patel, M.R. Baer, S.E. Bates, M.M. Gottesman

Research output: Contribution to journalLiterature review

Abstract

Resistance to chemotherapy remains a challenging issue for patients and their physicians. P-glycoprotein (Pgp, MDR1, ABCB1), as well as a family of structurally and functionally related proteins, are plasma membrane transporters able to efflux a variety of substrates from the cell cytoplasm, including chemotherapeutic agents. The discovery of ABCB1 made available a potential target for pharmacologic down-regulation of efflux-mediated chemotherapy resistance. In patients with acute myeloid leukemia (AML), a neoplasm characterized by proliferation of poorly differentiated myeloid progenitor cells, leukemic cells often express ABCB1 at high levels, which may lead to the development of resistance to chemotherapy. Thus, AML seemed to be a likely cancer for which the addition of drug efflux inhibitors to the chemotherapeutic regimen would improve outcomes in patients. Despite this rational hypothesis, the majority of clinical trials evaluating this strategy have failed to reach a positive endpoint, most recently the Eastern Cooperative Oncology Group E3999 trial. Here we review data suggesting the importance of ABCB1 in AML, address the failure of clinical trials to support a therapeutic strategy aimed at modulating ABCB1-mediated resistance, and consider the type of research that should be conducted in this field going forward.
Original languageEnglish
Pages (from-to)62-69
Number of pages8
JournalDrug Resistance Updates
Volume15
Issue number1-2
DOIs
Publication statusPublished - 1 Feb 2012

Fingerprint

Drug Resistance
Acute Myeloid Leukemia
Drug Therapy
Clinical Trials
Myeloid Progenitor Cells
Membrane Transport Proteins
P-Glycoprotein
Neoplasms
Cytoplasm
Therapeutics
Down-Regulation
Cell Membrane
Physicians
Research
Pharmaceutical Preparations
Proteins

Cite this

Shaffer, B.C. ; Gillet, J.-P. ; Patel, C. ; Baer, M.R. ; Bates, S.E. ; Gottesman, M.M. / Drug resistance : Still a daunting challenge to the successful treatment of AML. In: Drug Resistance Updates. 2012 ; Vol. 15, No. 1-2. pp. 62-69.
@article{b45d25a248f145be8224400bbea33341,
title = "Drug resistance: Still a daunting challenge to the successful treatment of AML",
abstract = "Resistance to chemotherapy remains a challenging issue for patients and their physicians. P-glycoprotein (Pgp, MDR1, ABCB1), as well as a family of structurally and functionally related proteins, are plasma membrane transporters able to efflux a variety of substrates from the cell cytoplasm, including chemotherapeutic agents. The discovery of ABCB1 made available a potential target for pharmacologic down-regulation of efflux-mediated chemotherapy resistance. In patients with acute myeloid leukemia (AML), a neoplasm characterized by proliferation of poorly differentiated myeloid progenitor cells, leukemic cells often express ABCB1 at high levels, which may lead to the development of resistance to chemotherapy. Thus, AML seemed to be a likely cancer for which the addition of drug efflux inhibitors to the chemotherapeutic regimen would improve outcomes in patients. Despite this rational hypothesis, the majority of clinical trials evaluating this strategy have failed to reach a positive endpoint, most recently the Eastern Cooperative Oncology Group E3999 trial. Here we review data suggesting the importance of ABCB1 in AML, address the failure of clinical trials to support a therapeutic strategy aimed at modulating ABCB1-mediated resistance, and consider the type of research that should be conducted in this field going forward.",
author = "B.C. Shaffer and J.-P. Gillet and C. Patel and M.R. Baer and S.E. Bates and M.M. Gottesman",
year = "2012",
month = "2",
day = "1",
doi = "10.1016/j.drup.2012.02.001",
language = "English",
volume = "15",
pages = "62--69",
journal = "Drug Resistance Updates",
issn = "1368-7646",
publisher = "Churchill Livingstone",
number = "1-2",

}

Drug resistance : Still a daunting challenge to the successful treatment of AML. / Shaffer, B.C.; Gillet, J.-P.; Patel, C.; Baer, M.R.; Bates, S.E.; Gottesman, M.M.

In: Drug Resistance Updates, Vol. 15, No. 1-2, 01.02.2012, p. 62-69.

Research output: Contribution to journalLiterature review

TY - JOUR

T1 - Drug resistance

T2 - Still a daunting challenge to the successful treatment of AML

AU - Shaffer, B.C.

AU - Gillet, J.-P.

AU - Patel, C.

AU - Baer, M.R.

AU - Bates, S.E.

AU - Gottesman, M.M.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Resistance to chemotherapy remains a challenging issue for patients and their physicians. P-glycoprotein (Pgp, MDR1, ABCB1), as well as a family of structurally and functionally related proteins, are plasma membrane transporters able to efflux a variety of substrates from the cell cytoplasm, including chemotherapeutic agents. The discovery of ABCB1 made available a potential target for pharmacologic down-regulation of efflux-mediated chemotherapy resistance. In patients with acute myeloid leukemia (AML), a neoplasm characterized by proliferation of poorly differentiated myeloid progenitor cells, leukemic cells often express ABCB1 at high levels, which may lead to the development of resistance to chemotherapy. Thus, AML seemed to be a likely cancer for which the addition of drug efflux inhibitors to the chemotherapeutic regimen would improve outcomes in patients. Despite this rational hypothesis, the majority of clinical trials evaluating this strategy have failed to reach a positive endpoint, most recently the Eastern Cooperative Oncology Group E3999 trial. Here we review data suggesting the importance of ABCB1 in AML, address the failure of clinical trials to support a therapeutic strategy aimed at modulating ABCB1-mediated resistance, and consider the type of research that should be conducted in this field going forward.

AB - Resistance to chemotherapy remains a challenging issue for patients and their physicians. P-glycoprotein (Pgp, MDR1, ABCB1), as well as a family of structurally and functionally related proteins, are plasma membrane transporters able to efflux a variety of substrates from the cell cytoplasm, including chemotherapeutic agents. The discovery of ABCB1 made available a potential target for pharmacologic down-regulation of efflux-mediated chemotherapy resistance. In patients with acute myeloid leukemia (AML), a neoplasm characterized by proliferation of poorly differentiated myeloid progenitor cells, leukemic cells often express ABCB1 at high levels, which may lead to the development of resistance to chemotherapy. Thus, AML seemed to be a likely cancer for which the addition of drug efflux inhibitors to the chemotherapeutic regimen would improve outcomes in patients. Despite this rational hypothesis, the majority of clinical trials evaluating this strategy have failed to reach a positive endpoint, most recently the Eastern Cooperative Oncology Group E3999 trial. Here we review data suggesting the importance of ABCB1 in AML, address the failure of clinical trials to support a therapeutic strategy aimed at modulating ABCB1-mediated resistance, and consider the type of research that should be conducted in this field going forward.

UR - http://www.scopus.com/inward/record.url?scp=84860689257&partnerID=8YFLogxK

U2 - 10.1016/j.drup.2012.02.001

DO - 10.1016/j.drup.2012.02.001

M3 - Literature review

AN - SCOPUS:84860689257

VL - 15

SP - 62

EP - 69

JO - Drug Resistance Updates

JF - Drug Resistance Updates

SN - 1368-7646

IS - 1-2

ER -